# Evaluating Adverse Outcomes After Myringotomy or Tube Placement in Head and Neck Cancer

**Authors:** Krithika Kuppusamy, Carly Y. Yang, Kevin Wong, Douglas C. Bigelow, Michael J. Ruckenstein, Steven J. Eliades, Jason A. Brant, Tiffany Hwa

PMC · DOI: 10.1002/ohn.1186 · Otolaryngology--Head and Neck Surgery · 2025-03-19

## TL;DR

This study found that patients with a history of head and neck cancer face a higher risk of persistent ear drum perforation after ear tube surgery compared to non-cancer patients.

## Contribution

The study identifies a significantly increased risk of persistent tympanic membrane perforation in cancer patients undergoing myringotomy.

## Key findings

- Cancer patients had a three-to-five-fold higher risk of persistent tympanic membrane perforation.
- There was no significant difference in overall adverse outcomes or recurrent effusion rates between cancer and non-cancer patients.
- Perforation risk was found to be influenced by multiple factors in multivariate analysis.

## Abstract

Evaluate rates of adverse outcomes among patients with a history of head and neck cancer undergoing myringotomy with or without tube placement for middle ear effusion.

Retrospective chart review.

Academic medical center.

Retrospective chart review was performed on patients undergoing myringotomy with or without tube placement for middle ear effusion between 2018 and 2022. Data reviewed included demographics, cancer history, audiometry, and clinical course.

In total, 578 patients (736 ears) had a mean follow‐up of 36.6 months: 84 (14.53%) were in the cancer cohort. On average, cancer patients were older (62.6 vs 59.3 years, P < .05) but had similar rates of overall adverse outcomes (44.05% vs 44.13%, P = 1.0). Rates of persistent perforation were higher among cancer patients (14.29% vs 2.43%, P < .001); there was no significant difference in rates of recurrent effusion (5.95% vs 4.66%; P = .81). Postpropensity score matching, perforation rates reached statistical significance (14.29% vs 1.22%, P < .01). There was no difference in rate of adverse events for overall events (44.05% vs 47.56%, P = .77) or recurrent effusion (5.95% vs 1.22%, P = .22).

Patients with a history of head and neck cancer or radiation have a three‐to‐five‐fold risk of persistent tympanic membrane perforation after myringotomy with or without tube placement and a higher rate of recurrent effusion that is not significant. In multivariate analysis, perforation risk was revealed to be multifactorial.

## Linked entities

- **Diseases:** head and neck cancer (MONDO:0005627)

## Full-text entities

- **Diseases:** middle ear effusion (MESH:D010034), Head and Neck Cancer (MESH:D006258), effusion (MESH:D000080324), tympanic membrane perforation (MESH:D018058), cancer (MESH:D009369), perforation (MESH:D057112)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12120037/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12120037/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12120037/full.md

---
Source: https://tomesphere.com/paper/PMC12120037